查看購物車
  • English
  • Japanese
  • Korean
青光眼治療市場（2026-2036）：疾病概述、開發平臺、監管趨勢與預測
市場調查報告書
商品編碼
2112470

青光眼治療市場（2026-2036）：疾病概述、開發平臺、監管趨勢與預測

The Glaucoma Drugs Market 2026 to 2036: Disease Landscape, Pipeline, Regulatory Dynamics and Forecasts
出版日期: | 出版商: SNS Research | 英文 257 Pages; 90 Tables & Figures | 商品交期: 最快1-2個工作天內

價格

這份題為「青光眼治療市場（2026-2036）－疾病概述、開發平臺、監管趨勢及預測」的報告，基於2026年至2036年的預測數據和2021年的歷史數據，對青光眼治療市場進行了詳細分析。報告涵蓋了該疾病的生物學特徵、主要適應症、已通過核准療法和學名藥的趨勢、研發開發平臺、主要市場的監管和報銷框架、給藥途徑的創新、未來發展藍圖、價值鏈分析、競爭格局以及針對市場參與企業的戰略建議。此外，報告還包含了領先的青光眼治療研發公司的簡介和策略。

市場規模預測以七大適應症、六大藥物類別、三大分銷管道、品牌藥和學名藥供應、五大區域市場以及26個各國市場進行細分。研發管線分析涵蓋七大作用機制類別的53個正在進行的臨床和臨床前項目。

本報告包含一套完整的 Excel 資料表，其中包含青光眼治療的所有定量預測資料和流程資料集。

「青光眼治療市場（2026-2036）—疾病概述、開發平臺、監管趨勢和預測」

摘要：青光眼是視神經進行性損傷的總稱，也是全球不可逆性失明的主要原因。視神經損傷會導致永久性周邊視力喪失，最終導致中心視力喪失。雖然眼壓升高是主要的、可控制的危險因素，但即使眼壓正常，也有相當一部分患者會出現視神經損傷。由於視力一旦喪失便無法恢復，因此治療的目標是延緩病情進展，而不是恢復視力。

藥物治療仍然是大多數青光眼適應症的第一線治療方案，其次是雷射治療和手術切除。眼藥水作為標準治療方案已沿用40年，其中前列腺素類似物自1990年代末期以來一直是首選治療方案。隨後，ROCK抑制劑、緩釋前房植入和不含防腐劑的固定劑量組合藥物拓寬了治療選擇，而具有神經保護作用或作用機制與眼壓無關的藥物目前正處於臨床研發的中期階段。

全球青光眼治療市場預計到 2026 年將超過 100 億美元，並在 2036 年前以中等個位數百分比的複合年成長率成長。這一成長是由人口老化、亞洲地區患病率上升、成像技術改進帶來的早期診斷以及治療選擇範圍擴大（包括正常眼壓性青光眼）所驅動的。

基於前列腺素的治療模式正在經歷結構性變革。 ROCK抑制劑作為一種作用機制全新的藥物，在20多年來首次獲準用於治療青光眼；緩釋型眼內植入正將治療從藥房轉移到診室；不含防腐劑的固定劑量組合藥物正在整合多劑量滴眼療法。同時，現有產品的一般化也在重塑定價、醫保覆蓋範圍以及原廠藥的市場佔有率。

正常眼壓性青光眼是指視神經損傷在眼壓不升高的情況下進展，傳統療法無法有效治療此類疾病，目前已被正式納入多個中期臨床試驗項目。為了滿足這一未被滿足的醫療需求，研究人員正在開發一些不依賴眼壓的作用機制，例如KATP通道調節和神經保護作用；同時，他們也在開發給藥平台，以解決長期眼壓治療中存在的用藥依從性問題。

給藥平台是正在進行的研發項目中的重要組成部分，這反映了該領域面臨的一項核心商業性挑戰：長期滴眼治療的依從性低。在研候選產品包括前房及玻璃體內植入、淚小管栓塞、藥物緩釋隱形眼鏡及人工人工水晶體輪匝肌、微噴霧劑、經皮眼瞼給藥。

這份題為「2026-2036年青光眼治療市場－疾病整體情況、研發管線、監管趨勢及預測」的報告，基於2026年至2036年的預測數據和2021年的歷史數據，對青光眼治療市場進行了詳細評估。報告涵蓋了該疾病的生物學特徵、主要應用領域、已通過核准療法和學名藥的趨勢、開發平臺、主要市場的監管和報銷框架、給藥途徑創新、未來發展藍圖、價值鏈分析、競爭格局以及針對市場參與企業的戰略建議。此外，報告還包含了領先的青光眼治療研發公司的簡介和策略。

市場規模預測按七大適應症、六大藥物類別、三大分銷管道、品牌藥和學名藥供應、五大區域市場以及26個各國市場進行細分。研發管線分析涵蓋七大作用機制類別的53個正在進行的臨床和臨床前項目。

本報告包含一套完整的 Excel 資料表，其中包含所有定量預測資料和青光眼治療流程的完整資料集。

主要發現：

本報告包含以下主要結論：

  • 全球青光眼治療市場預計到 2026 年將超過 100 億美元，並在 2036 年之前以中等個位數的複合年成長率成長。這主要受人口老化、亞洲地區患病率上升、影像技術改進帶來的早期診斷以及治療方案擴展到包括與眼壓無關的疾病等因素的推動。
  • 基於前列腺素的治療模式正在經歷結構性變革。繼2014年日本利帕地爾（lipasdil）和2017年美國奈他地爾（netalusdil）獲批後，ROCK抑制劑作為一類具有全新作用機制的新型藥物脫穎而出，標誌著20多年來首個獲批的青光眼治療藥物問世。 2025年10月，頭孢前列素（cepetaprost）作為最新一款具有全新作用機制的藥物進入日本市場。
  • 隨著緩釋脈絡膜內注射技術的出現，青光眼治療正從藥局轉移到診間。 2020年Durista、2023年iDose TR的核准，以及FDA於2026年1月核准的重複給藥方案，使得單劑量植入轉變為可調式植入物。這種轉變不僅改變了醫療報銷模式，也改變了醫療服務提供地點，將以往的藥房報銷改為包含藥物和手術兩部分的費用報銷。
  • 對於正常眼壓性青光眼，即視神經損傷在眼壓未升高的情況下進展，傳統的降眼壓療法仍不足。目前，該疾病已被列入多個中期臨床試驗項目的適應症，研究人員正在開發不依賴眼壓的作用機制，包括KATP通道調節，以滿足此未被滿足的醫療需求。
  • 青光眼治療藥物研發正進入作用機轉最多樣化的時期。本報告概述了正在進行的臨床和臨床前項目，涵蓋類前列腺素調節、ROCK抑制、腎上腺素能調節、KATP通道調節、一氧化氮供體、神經保護以及細胞、基因和RNA療法等。
  • 神經保護是目前在研領域中真正創新生物學方法最為集中，同時也面臨監管不確定性最高的領域。所有已通過核准的青光眼療法都是基於降低眼內壓而核准的，尚無基於功能或結構終點指標核准的案例。該領域面臨的關​​鍵挑戰並非檢驗作用機制，而是如何確定終點指標。
  • 細胞和基因療法首次被引入青光眼的臨床治療。 ER-100將於2026年6月啟動針對開放性青光眼和非動脈性前部缺血性視神經病變的I期臨床試驗；NT-501已於2025年獲批用於治療黃斑毛細血管擴張症，目前正在進行針對青光眼相關視力障礙的II期臨床試驗。
  • 亞太地區、中東和非洲以及拉丁美洲和中美洲等新興市場預計將高於全球平均水平，這得益於不斷擴大的專業醫療保健基礎設施、改進的保險報銷制度以及學名藥的廣泛供應。

討論主題：

本報告涵蓋以下主題：

  • 全球青光眼治療市場規模、市場區隔及2021年至2036年預測。
  • 市場促進因素、障礙和宏觀經濟趨勢
  • 已通過核准的藥物類別和主要市場產品，適用於所有主要青光眼適應症
  • 對 53 種有前景的候選藥物的開發平臺進行審查。
  • 先進的藥物傳輸技術與緩釋創新平台
  • 2036 年前青光眼藥物研發未來藍圖
  • 青光眼治療藥物價值鏈分析
  • 主要生態系統參與者的企業概況和策略
  • 競爭格局，包括收購、合作和授權活動
  • 美國、歐盟、英國、日本和中國的法律規範與報銷機制
  • 2017 年以來品牌藥中現有學名藥之間的競爭、第四段訴訟、專利格局。
  • 為開發公司、投資者和醫療保健相關人員提供的策略建議

本報告主要解答以下問題：

本報告解答以下關鍵問題：

  • 2026年全球青光眼治療市場規模將達到多少？ 2036年又將如何發展？
  • 推動市場成長的結構性因素是什麼？限制市場成長的障礙又是什麼？
  • 關鍵類別的成長率與目標品牌藥品的銷售額有何關係？開發商和投資者應該如何在他們的模型中反映這一點？
  • 一般化的出現如何重塑現有品牌藥和 2017 年以來推出的品牌藥的價格、處方趨勢和市場佔有率？
  • 到 2036 年，哪些適應症、藥物類別、劑型和分銷管道將帶來最高的成長？
  • 哪些國家或地區市場具有最大的成長潛力？哪些因素正在推動區域格局的重新平衡？
  • 除了已確診的開放性青光眼之外，還有哪些適應症正在出現，成為獨特的商業性機會？又有哪些機制可以解決這些問題呢？
  • 哪些緩釋製劑和替代給藥平台正在推動核准進程？它們將如何改變競爭動態和報銷模式？
  • 這個市場的參與企業有哪些？他們正在採取哪些策略？
  • 為了在 2036 年前最大限度地掌握市場機遇，製藥開發公司、投資者和醫療保健相關人員應該採取哪些策略？

預測分割：

本報告對青光眼治療市場的多個方面進行了詳細的銷售預測，其中包括：

適應症

  • 原發性開放性青光眼（POAG）
  • 高眼壓性開放性青光眼（POAG）
  • 正常眼壓性青光眼（NTG）
  • 原發性隅角閉鎖性青光眼（PACG）
  • 眼高壓（OHT）
  • 續發性青光眼
  • 先天性青光眼

藥物分類

  • 前列腺素類似物
  • BETA阻斷劑
  • α促效劑
  • 碳酸酐酶抑制劑
  • ROCK（Rho激酶）抑制劑
  • 同時服用的藥物及其他

品牌藥和學名藥

  • 品牌藥品
  • 學名藥

通路

  • 醫院和專科藥房
  • 零售藥房
  • 線上藥局/D2C

當地市場

  • 亞太地區
  • 歐洲
  • 中東和非洲
  • 北美洲
  • 拉丁美洲和中美洲

按國家/地區分類的市場

  • 澳洲
  • 巴西
  • 加拿大
  • 中國
  • 埃及
  • 法國
  • 德國
  • 希臘
  • 印度
  • 以色列
  • 義大利
  • 日本
  • 墨西哥
  • 荷蘭
  • 波蘭
  • 葡萄牙
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 韓國
  • 西班牙
  • 瑞士
  • 台灣
  • 土耳其
  • 英國
  • 美國

目錄

第1章：引言

第2章：青光眼治療藥物概述

  • 什麼是青光眼？
  • 什麼原因會導致青光眼？
  • 青光眼的類型
  • 藥物在青光眼治療中的作用
  • 其他治療方案
  • 市場成長促進因素
  • 抑制市場成長的因素

第3章：藥物類別和主要治療方法的可近性

  • 藥物類別的可用性
  • 主要青光眼藥物
  • 專利到期和學名藥的競爭

第4章：研發開發平臺及新療法展望

  • 新藥研發的關鍵領域
  • 對青光眼藥物開發平臺中的關鍵候選藥物進行綜述

第5章：青光眼治療藥物的未來發展藍圖與價值鏈

  • 未來藍圖
  • 價值鏈

第6章：青光眼治療藥物的監管現狀

  • 美國：FDA監管路徑
  • 歐盟和英國
  • 日本：PMDA率先實施年度價格調整。
  • 中國：國家藥品管理局、國家藥品研究院和數量採購
  • 學名藥法規結構
  • 後期開發項目的監理認定概況
  • 神經保護終點存在問題
  • 監理情勢：商業性影響

第7章 主要市場參與企業

  • AbbVie Inc.
  • Alcon Inc.
  • Allysta Pharmaceuticals
  • Amorphex Therapeutics
  • Astellas Pharma
  • Bausch + Lomb
  • Bayer AG
  • Betaliq
  • BioAxone Biosciences
  • BioLight Life Sciences Ltd.
  • Accure Therapeutics
  • D.Western Therapeutics Institute Inc.
  • Optus Pharmaceuticals Co., Ltd.
  • Dompe Farmaceutici
  • PulseSight Therapeutics SAS
  • Fera Pharmaceuticals LLC
  • Fidia Farmaceutici SpA
  • Glaukos Corporation
  • HitGen Inc.
  • ID Pharma Co.
  • InMed Pharmaceuticals
  • Isarna Therapeutics
  • Kowa Company
  • Laboratorios SALVAT SA
  • Laboratorios Sophia
  • Life Biosciences
  • Mannin Research
  • Mati Therapeutics Inc.
  • MediPrint Ophthalmics
  • MimeTech Srl
  • Mundipharma International Limited
  • Neurotech Pharmaceuticals Inc.
  • Nicox
  • Novaliq GmbH
  • Novartis
  • Ocular Therapeutix Inc.
  • Oculis Holding AG
  • Nanogenics
  • Oncolys BioPharma Inc.
  • ONO Pharmaceutical
  • Opus Genetics
  • Otero Therapeutics
  • Otsuka Pharmaceutical Co.
  • Peregrine Ophthalmic
  • Perfuse Therapeutics Inc.
  • Pfizer Inc.
  • pH Pharma Co
  • PolyActiva
  • Q BioMed Inc.
  • Qlaris Bio Inc.
  • Radikal Therapeutics
  • Regeneron Pharmaceuticals Inc.
  • Replenish Inc.
  • Roche Holding (F. Hoffmann-La Roche)
  • Santen Pharmaceutical Company
  • Senju Pharmaceutical Company
  • SPARC (Sun Pharma Advanced Research Company)
  • Taejoon Pharm
  • Laboratories THEA
  • TikoMed
  • UBE Corporation
  • Wakamoto Company

第8章：市場規模的計算與預測

  • 全球青光眼治療藥物展望
  • 藥物分類細分
  • 按適應症細分
  • 分銷通路細分
  • 按原廠藥和非專利處方藥細分
  • 區域細分
  • 主要各國市場
    • 澳洲
    • 巴西
    • 加拿大
    • 中國
    • 埃及
    • 法國
    • 德國
    • 希臘
    • 印度
    • 以色列
    • 義大利
    • 日本
    • 墨西哥
    • 荷蘭
    • 波蘭
    • 葡萄牙
    • 俄羅斯
    • 沙烏地阿拉伯
    • 南非
    • 韓國
    • 西班牙
    • 瑞士
    • 台灣
    • 土耳其
    • 英國
    • 美國
    • 世界其他地區
  • 發起策略的商業性影響

第9章：結論與策略建議

  • 市場預期成長的原因有哪些？
  • 競爭格局：收購、合作與併購
  • 已獲批准的藥物先例重塑了治療模式。
  • 研發開發平臺回顧：新療法的展望
  • 專利到期和學名藥的競爭
  • MIGS和程序性競爭威脅
  • 聯合治療產品
  • 不依賴眼內壓的神經保護療法
  • 提高患者用藥依從性
  • 新的製劑和給藥途徑
  • 區域展望：哪個國家成長潛力最大？
  • 哪一類藥物在市場上佔主導地位？
  • 策略建議
  • 哪家發起機構的表現會優於基準情境？

The “Glaucoma Drugs Market 2026 to 2036: Disease Landscape, Pipeline, Regulatory Dynamics and Forecasts” report presents an in-depth assessment of the glaucoma drugs market with forecasts from 2026 to 2036 and historical data from 2021. It covers disease biology and key application areas, approved therapies and generic dynamics, the R&D pipeline, regulatory and reimbursement frameworks across major markets, delivery route innovation, the future roadmap, value chain analysis, competitive dynamics, and strategic recommendations for market participants. The report additionally includes profiles and strategies of leading glaucoma drug developers.

Market size forecasts are segmented across 7 indications, 6 drug classes, 3 distribution channels, branded and generic supply, 5 regional markets, and 26 country markets. The pipeline analysis covers 53 active clinical and preclinical programs across seven mechanistic classes.

The report is accompanied by an Excel datasheet suite covering all quantitative forecast data and the full glaucoma drug pipeline dataset.

The Glaucoma Drugs Market 2026 to 2036: Disease Landscape, Pipeline, Regulatory Dynamics and Forecasts

Synopsis: Glaucoma is a group of progressive optic neuropathies and the leading cause of irreversible blindness worldwide. Damage to the optic nerve produces permanent loss of peripheral and ultimately central vision. Elevated intraocular pressure is the principal modifiable risk factor, yet a substantial portion of patients experience optic nerve damage despite normal-range pressures. Because vision already lost cannot be recovered, treatment is directed at slowing progression rather than restoring function.

Drug therapy remains the first-line intervention across most glaucoma indications, ahead of laser treatment and incisional surgery. Topical eye drops have defined the treatment paradigm for four decades, and prostaglandin analogs have anchored first-line therapy since the late 1990s. ROCK inhibitors, sustained-release intracameral implants, and preservative-free fixed-dose combinations have since broadened the format landscape, while neuroprotective and pressure-independent mechanisms are advancing through mid-stage development.

The global glaucoma drugs market is forecast to exceed $10 billion in 2026 and to expand at a mid single-digit CAGR through 2036. Growth is supported by aging populations, rising prevalence across Asia, earlier diagnosis through improved imaging, and the expansion of treatment into normal-tension disease.

The prostaglandin-anchored treatment paradigm is in structural transition. ROCK inhibitors arrived as the first new mechanism class approved for glaucoma in over two decades, sustained-release intracameral implants have moved therapy out of the pharmacy and into the procedure room, and preservative-free fixed-dose combinations are consolidating multi-drop regimens. Genericization across the established base is simultaneously reshaping pricing, formulary dynamics, and originator share.

Normal-tension glaucoma, in which optic nerve damage progresses without elevated pressure, is poorly served by conventional therapy and is now a named indication across several mid-stage programs. Pressure-independent mechanisms including KATP channel modulation and neuroprotection are advancing against that unmet need, alongside delivery platforms addressing the adherence problem in chronic topical therapy.

Delivery platforms account for a substantial share of active development programs, reflecting the central commercial problem in the category, which is poor adherence to chronic topical therapy. Candidates in development span intracameral and intravitreal implants, punctal plugs, drug-eluting contact lenses and intraocular lenses, ocular rings, microdose sprays, and transdermal eyelid delivery.

The“Glaucoma Drugs Market 2026 to 2036: Disease Landscape, Pipeline, Regulatory Dynamics and Forecasts” report presents an in-depth assessment of the glaucoma drugs market with forecasts from 2026 to 2036 and historical data from 2021. It covers disease biology and key application areas, approved therapies and generic dynamics, the R&D pipeline, regulatory and reimbursement frameworks across major markets, delivery route innovation, the future roadmap, value chain analysis, competitive dynamics, and strategic recommendations for market participants. The report additionally includes profiles and strategies of leading glaucoma drug developers.

Market size forecasts are segmented across 7 indications, 6 drug classes, 3 distribution channels, branded and generic supply, 5 regional markets, and 26 country markets. The pipeline analysis covers 53 active clinical and preclinical programs across seven mechanistic classes.

The report is accompanied by an Excel datasheet suite covering all quantitative forecast data and the full glaucoma drug pipeline dataset.

Key Findings:

The report has the following key findings:

  • The global glaucoma drugs market is forecast to exceed $10 billion in 2026 and to expand at a mid single-digit CAGR through 2036, supported by aging populations, rising prevalence across Asia, earlier diagnosis through improved imaging, and the extension of treatment into pressure-independent disease.
  • The prostaglandin-anchored treatment paradigm is in structural transition. ROCK inhibitors arrived as the first new mechanism class approved for glaucoma in over two decades, following Japan's approval of ripasudil in 2014 and the US approval of netarsudil in 2017, and sepetaprost reached the Japanese market in October 2025 as the most recent novel mechanism to launch.
  • Sustained-release intracameral delivery is moving glaucoma therapy out of the pharmacy and into the procedure room. Durysta was approved in 2020 and iDose TR in 2023, and the FDA approval of a repeat-treatment protocol in January 2026 converted a single-administration implant into a re-administrable one. The shift replaces a pharmacy benefit claim with a dual-component drug and procedure claim, which changes both the reimbursement model and the site of care.
  • Normal-tension glaucoma, in which optic nerve damage progresses without elevated intraocular pressure, remains poorly served by conventional pressure-lowering therapy. It is now a named indication across several mid-stage programs, and pressure-independent mechanisms including KATP channel modulation are advancing against that unmet need.
  • The glaucoma pipeline is entering its most mechanistically diverse period. This report profiles active clinical and preclinical programs spanning prostanoid modulation, ROCK inhibition, adrenergic modulation, KATP channel modulation, nitric oxide donation, neuroprotection, and cell, gene, and RNA therapy.
  • Neuroprotection represents the largest concentration of genuinely novel biology in the pipeline and carries the most regulatory uncertainty. Every approved glaucoma drug is indicated on the basis of intraocular pressure reduction, and no functional or structural endpoint has yet supported an approval. Endpoint negotiation rather than mechanism validation is the gating task for this cohort.
  • Cell and gene therapy has entered the glaucoma clinic for the first time. ER-100 began Phase 1 dosing in June 2026 in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, and NT-501 is in Phase 2 for glaucoma-related visual impairment following its 2025 approval in macular telangiectasia.
  • Emerging markets across Asia Pacific, Middle East & Africa, and Latin & Central America are projected to grow above the global average, supported by expanding specialist infrastructure, improving reimbursement, and broad generic accessibility.

Topics Covered:

The report covers the following topics:

  • Global glaucoma drugs market sizing, segmentation, and forecasts from 2021 to 2036
  • Market drivers, barriers, and macro-environmental trends
  • Approved drug classes and leading commercial products across all major glaucoma indications
  • Development pipeline review across 53 active candidates
  • Advanced drug delivery technologies and sustained-release innovation platforms
  • Future roadmap for glaucoma drug development to 2036
  • Glaucoma drugs value chain analysis
  • Company profiles and strategies of leading ecosystem players
  • Competitive landscape including acquisitions, alliances, and licensing activity
  • Regulatory frameworks and reimbursement mechanisms across the US, EU, UK, Japan, and China
  • Generic competition, Paragraph IV litigation, and the patent landscape across established and post-2017 branded agents
  • Strategic recommendations for developers, investors, and healthcare stakeholders

Key Questions Answered:

The report provides answers to the following key questions:

  • How large is the global glaucoma drugs market in 2026 and how will it evolve through 2036?
  • What structural forces are driving market growth and what barriers constrain it?
  • How do headline category growth and addressable branded revenue relate to one another, and how should developers and investors reflect that in their models?
  • How is genericization reshaping pricing, formulary dynamics, and originator share across established and post-2017 branded agents?
  • Which indications, drug classes, delivery formats, and distribution channels will generate the highest growth through 2036?
  • Which country and regional markets offer the highest growth potential and what is driving geographic rebalancing?
  • Which indications are emerging as distinct commercial opportunities beyond established open-angle disease, and which mechanisms are positioned to serve them?
  • What sustained-release and alternative delivery platforms are advancing toward approval, and how will they alter the competitive dynamic and the reimbursement model?
  • Who are the leading market participants and what strategies are they pursuing?
  • What strategies should drug developers, investors, and healthcare stakeholders adopt to capitalize on market opportunities through 2036?

Forecast Segmentation:

The report provides detailed revenue forecasts across multiple dimensions of the Glaucoma Drugs market, including:

Indication

  • Primary Open-Angle Glaucoma (POAG)
  • High-Tension POAG
  • Normal-Tension Glaucoma (NTG)
  • Primary Angle-Closure Glaucoma (PACG)
  • Ocular Hypertension (OHT)
  • Secondary Glaucoma
  • Congenital Glaucoma

Drug Class

  • Prostaglandin Analogs
  • Beta Blockers
  • Alpha Agonists
  • Carbonic Anhydrase Inhibitors
  • ROCK (Rho Kinase) Inhibitors
  • Combinations & Others

Originator vs Generic

  • Branded Drugs
  • Generic Drugs

Distribution Channel

  • Hospital / Specialty Pharmacies
  • Retail Pharmacy
  • Online Pharmacies / D2C

Regional Markets

  • Asia Pacific
  • Europe
  • Middle East & Africa
  • North America
  • Latin & Central America

Country Markets

  • Australia
  • Brazil
  • Canada
  • China
  • Egypt
  • France
  • Germany
  • Greece
  • India
  • Israel
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Saudi Arabia
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey
  • UK
  • USA

Table of Contents

Chapter 1: Introduction

  • 1.1 Executive Summary
  • 1.2 Topics Covered
  • 1.3 Forecast Segmentation
  • 1.4 Key Questions Answered
  • 1.5 Key Findings
  • 1.6 Methodology
  • 1.7 Target Audience
  • 1.8 Companies & Organizations Mentioned
    • 1.8.1 Companies
    • 1.8.2 Regulatory Bodies & Organizations

Chapter 2: An Overview of Glaucoma Drugs

  • 2.1 What is Glaucoma?
  • 2.2 What Causes Glaucoma?
    • 2.2.1 Excessive IOP (Intraocular Pressure)
    • 2.2.2 How Does Pressure Build Up in the Eye?
    • 2.2.3 NTG (Normal-Tension Glaucoma)
    • 2.2.4 Related Conditions
      • 2.2.4.1 Ocular Hypertension
      • 2.2.4.2 Glaucoma Suspects
  • 2.3 Types of Glaucoma
    • 2.3.1 Open-Angle Glaucoma
    • 2.3.2 Angle-Closure Glaucoma
    • 2.3.3 Secondary Glaucoma
    • 2.3.4 Congenital Glaucoma
    • 2.3.5 Iridocorneal Endothelial (ICE) Syndrome
  • 2.4 The Role of Drugs in Glaucoma Treatment
    • 2.4.1 Eye Drops
    • 2.4.2 Injections
    • 2.4.3 Oral Pills
  • 2.5 Other Treatment Options
    • 2.5.1 Laser Treatment
    • 2.5.2 Surgery
    • 2.5.3 MIGS
  • 2.6 Market Growth Drivers
    • 2.6.1 Impact of Glaucoma on Daily Life
    • 2.6.2 Growing Prevalence of Glaucoma
    • 2.6.3 Longevity on the Rise
    • 2.6.4 Advances in Drug Delivery Technologies
    • 2.6.5 Other Factors
  • 2.7 Market Barriers
    • 2.7.1 Patient Compliance & Lack of Awareness
    • 2.7.2 Alternative Healing Options
    • 2.7.3 Innovator vs. Generic Disputes
    • 2.7.4 Lack of Healthcare Insurance
    • 2.7.5 Preservative-Related Ocular Surface Disease

Chapter 3: Drug Class Availability & Leading Therapies

  • 3.1 Drug Class Availability
    • 3.1.1 Prostaglandin Analogs
    • 3.1.2 Beta Blockers
    • 3.1.3 Alpha Agonists
    • 3.1.4 Carbonic Anhydrase Inhibitors
    • 3.1.5 ROCK (Rho Kinase) Inhibitors
    • 3.1.6 Combinations & Others
  • 3.2 Leading Glaucoma Drugs
    • 3.2.1 Prostaglandin Analogs
      • 3.2.1.1 Bimatoprost
      • 3.2.1.2 Catioprost
      • 3.2.1.3 Latanoprost
      • 3.2.1.4 Latanoprost Preservative-Free Solution
      • 3.2.1.5 Latanoprost Cationic Emulsion
      • 3.2.1.6 Latanoprostene Bunod
      • 3.2.1.7 Omidenepag Isopropyl
      • 3.2.1.8 Sepetaprost
      • 3.2.1.9 Tafluprost
      • 3.2.1.10 Travoprost
      • 3.2.1.11 Unoprostone Isopropyl
    • 3.2.2 Beta Blockers
      • 3.2.2.1 Betaxolol
      • 3.2.2.2 Carteolol
      • 3.2.2.3 Levobunolol
      • 3.2.2.4 Metipranolol
      • 3.2.2.5 Timolol
    • 3.2.3 Alpha Agonists
      • 3.2.3.1 Apraclonidine
      • 3.2.3.2 Brimonidine
    • 3.2.4 Carbonic Anhydrase Inhibitors
      • 3.2.4.1 Acetazolamide
      • 3.2.4.2 Brinzolamide
      • 3.2.4.3 Dorzolamide
      • 3.2.4.4 Methazolamide
    • 3.2.5 ROCK Inhibitors
      • 3.2.5.1 Netarsudil
      • 3.2.5.2 Netarsudil and Latanoprost
      • 3.2.5.3 Ripasudil
    • 3.2.6 Intracameral Sustained-Release Implants
      • 3.2.6.1 Bimatoprost Intracameral Implant
      • 3.2.6.2 Travoprost Intracameral Implant
    • 3.2.7 Fixed-Dose Combinations
      • 3.2.7.1 Brinzolamide and Brimonidine
      • 3.2.7.2 Brimonidine and Timolol
      • 3.2.7.3 Dorzolamide and Timolol
    • 3.2.8 Other and Adjunctive Agents
      • 3.2.8.1 Aflibercept
      • 3.2.8.2 Bevacizumab
      • 3.2.8.3 Carbachol
      • 3.2.8.4 Dipivefrin
      • 3.2.8.5 Pilocarpine
  • 3.3 The Patent Cliff and Generic Competition

Chapter 4: R&D Pipeline and Prospects of New Therapies

  • 4.1 Key Areas of New Drug Development
  • 4.2 Review of Key Glaucoma Pipeline Candidates
    • 4.2.1 Adrenergic Modulators
    • 4.2.2 Cell, Gene, and RNA Therapies
    • 4.2.3 KATP Channel Modulators
    • 4.2.4 Neuroprotective and Emerging Mechanisms
    • 4.2.5 Nitric Oxide Donors
    • 4.2.6 Prostanoid Modulators
    • 4.2.7 ROCK Inhibitors
    • 4.2.8 Compliance Imperative: Why Delivery Innovation Dominates Investment
    • 4.2.9 Near-Term Approval Horizon: What Reaches Market Before

Chapter 5: Glaucoma Drugs Future Roadmap & Value Chain

  • 5.1 Future Roadmap
    • 5.1.1 Pre-2030: Consolidation, Combination Therapies & Emerging Novel Drug Classes
    • 5.1.2 2030 - 2033: Maturation of Biologics, Gene Therapies & Disease-Modifying Approaches
    • 5.1.3 2033 - 2036 & Beyond: SR Delivery, Digital Integration & Personalized Glaucoma Management
    • 5.1.4 Roadmap Outlook
  • 5.2 Value Chain
    • 5.2.1 API Manufacturers & Enabling Technology Providers
    • 5.2.2 Generic Drug Manufacturers
    • 5.2.3 Innovator Pharmaceutical Companies
    • 5.2.4 Regional Distributors
    • 5.2.5 Healthcare Providers, Pharmacies & Drug Stores

Chapter 6: Glaucoma Drugs Regulatory Landscape

  • 6.1 United States: FDA Regulatory Pathways
    • 6.1.1 Primary Approval Pathways
    • 6.1.2 Expedited Development Programs
    • 6.1.3 Manufacturing and CMC Risk
    • 6.1.4 Reimbursement: Centers for Medicare and Medicaid Services
  • 6.2 European Union and United Kingdom
    • 6.2.1 United Kingdom: MHRA and the Relaunched ILAP
    • 6.2.2 HTA and Reimbursement: European Frameworks
  • 6.3 Japan: PMDA, Sakigake, and Annual Price Revision
  • 6.4 China: NMPA, NRDL, and Volume-Based Procurement
  • 6.5 Generic Drug Regulatory Frameworks
    • 6.5.1 United States: ANDA and Paragraph IV
    • 6.5.2 European Generic and Parallel Import Frameworks
    • 6.5.3 China: Generic Framework and Procurement
    • 6.5.4 Japan: Generic Substitution Framework
    • 6.5.5 Rest of World Generic and Regional Frameworks
  • 6.6 Regulatory Designation Profiles of Late-Stage Programs
  • 6.7 The Neuroprotection Endpoint Problem
  • 6.8 Regulatory Landscape: Commercial Implications

Chapter 7: Key Market Players

  • 7.1 AbbVie Inc.
  • 7.2 Alcon Inc.
  • 7.3 Allysta Pharmaceuticals
  • 7.4 Amorphex Therapeutics
  • 7.5 Astellas Pharma
  • 7.6 Bausch + Lomb
  • 7.7 Bayer AG
  • 7.8 Betaliq
  • 7.9 BioAxone Biosciences
  • 7.10 BioLight Life Sciences Ltd.
  • 7.11 Accure Therapeutics
  • 7.12 D.Western Therapeutics Institute Inc.
  • 7.13 Optus Pharmaceuticals Co., Ltd.
  • 7.14 Dompe Farmaceutici
  • 7.15 PulseSight Therapeutics SAS
  • 7.16 Fera Pharmaceuticals LLC
  • 7.17 Fidia Farmaceutici S.p.A.
  • 7.18 Glaukos Corporation
  • 7.19 HitGen Inc.
  • 7.20 ID Pharma Co.
  • 7.21 InMed Pharmaceuticals
  • 7.22 Isarna Therapeutics
  • 7.23 Kowa Company
  • 7.24 Laboratorios SALVAT S.A.
  • 7.25 Laboratorios Sophia
  • 7.26 Life Biosciences
  • 7.27 Mannin Research
  • 7.28 Mati Therapeutics Inc.
  • 7.29 MediPrint Ophthalmics
  • 7.30 MimeTech S.r.l.
  • 7.31 Mundipharma International Limited
  • 7.32 Neurotech Pharmaceuticals Inc.
  • 7.33 Nicox
  • 7.34 Novaliq GmbH
  • 7.35 Novartis
  • 7.36 Ocular Therapeutix Inc.
  • 7.37 Oculis Holding AG
  • 7.38 Nanogenics
  • 7.39 Oncolys BioPharma Inc.
  • 7.40 ONO Pharmaceutical
  • 7.41 Opus Genetics
  • 7.42 Otero Therapeutics
  • 7.43 Otsuka Pharmaceutical Co.
  • 7.44 Peregrine Ophthalmic
  • 7.45 Perfuse Therapeutics Inc.
  • 7.46 Pfizer Inc.
  • 7.47 pH Pharma Co
  • 7.48 PolyActiva
  • 7.49 Q BioMed Inc.
  • 7.50 Qlaris Bio Inc.
  • 7.51 Radikal Therapeutics
  • 7.52 Regeneron Pharmaceuticals Inc.
  • 7.53 Replenish Inc.
  • 7.54 Roche Holding (F. Hoffmann-La Roche)
  • 7.55 Santen Pharmaceutical Company
  • 7.56 Senju Pharmaceutical Company
  • 7.57 SPARC (Sun Pharma Advanced Research Company)
  • 7.58 Taejoon Pharm
  • 7.59 Laboratories THEA
  • 7.60 TikoMed
  • 7.61 UBE Corporation
  • 7.62 Wakamoto Company

Chapter 8: Market Sizing & Forecasts

  • 8.1 Global Outlook for Glaucoma Drugs
  • 8.2 Segmentation by Drug Class
    • 8.2.1 Prostaglandin Analogs
    • 8.2.2 Beta Blockers
    • 8.2.3 Alpha Agonists
    • 8.2.4 Carbonic Anhydrase Inhibitors
    • 8.2.5 ROCK Inhibitors
    • 8.2.6 Combinations & Others
  • 8.3 Segmentation by Indication
    • 8.3.1 Primary Open-Angle Glaucoma (POAG)
      • 8.3.1.1 High-Tension POAG
      • 8.3.1.2 Normal-Tension Glaucoma (NTG)
    • 8.3.2 Primary Angle-Closure Glaucoma (PACG)
    • 8.3.3 Ocular Hypertension (OHT)
    • 8.3.4 Secondary Glaucoma
    • 8.3.5 Congenital Glaucoma
  • 8.4 Segmentation by Distribution Channel
    • 8.4.1 Hospital / Specialty Pharmacies
    • 8.4.2 Retail Pharmacy
    • 8.4.3 Online Pharmacies / D2C
  • 8.5 Segmentation by Originator vs Generic Drugs
    • 8.5.1 Branded Drugs
    • 8.5.2 Generic Drugs
  • 8.6 Segmentation by Region
    • 8.6.1 Asia Pacific
    • 8.6.2 Europe
    • 8.6.3 Middle East & Africa
    • 8.6.4 Latin & Central America
    • 8.6.5 North America
  • 8.7 Top Country Markets
    • 8.7.1 Australia
    • 8.7.2 Brazil
    • 8.7.3 Canada
    • 8.7.4 China
    • 8.7.5 Egypt
    • 8.7.6 France
    • 8.7.7 Germany
    • 8.7.8 Greece
    • 8.7.9 India
    • 8.7.10 Israel
    • 8.7.11 Italy
    • 8.7.12 Japan
    • 8.7.13 Mexico
    • 8.7.14 Netherlands
    • 8.7.15 Poland
    • 8.7.16 Portugal
    • 8.7.17 Russia
    • 8.7.18 Saudi Arabia
    • 8.7.19 South Africa
    • 8.7.20 South Korea
    • 8.7.21 Spain
    • 8.7.22 Switzerland
    • 8.7.23 Taiwan
    • 8.7.24 Turkey
    • 8.7.25 UK
    • 8.7.26 USA
    • 8.7.27 Rest of the World (RoW)
  • 8.8 Commercial Implications for Originator Strategy

Chapter 9: Conclusion & Strategic Recommendations

  • 9.1 Why is the Market Poised to Grow?
  • 9.2 Competitive Industry Landscape: Acquisitions, Alliances & Consolidation
    • 9.2.1 Corporate Consolidation, 2019 - 2022
    • 9.2.2 Transactions Reshaping the Portfolio, 2024 - 2026
    • 9.2.3 Consolidated Competitive Positioning
  • 9.3 Approved Drug Precedents Reshaping the Treatment Paradigm
  • 9.4 R&D Pipeline Review: Prospects of New Therapies
    • 9.4.1 Sustained-Release Delivery
    • 9.4.2 ROCK Inhibitors
    • 9.4.3 Prostaglandin Receptor Agonists
    • 9.4.4 Nitric Oxide Donors
    • 9.4.5 KATP Channel Modulators
    • 9.4.6 Adenosine Receptor Modulators
    • 9.4.7 Cell, Gene, and RNA Therapies
    • 9.4.8 Recent Discontinuations and What They Signal
  • 9.5 The Patent Cliff and Generic Competition
    • 9.5.1 Patent Expiration and Generic Entry
    • 9.5.2 Regulatory and Reimbursement Dynamics Supporting Commercial Durability
  • 9.6 MIGS and the Procedural Competitive Threat
  • 9.7 Combination Therapy Products
  • 9.8 IOP-Independent and Neuroprotective Therapy
  • 9.9 Improving Patient Compliance
    • 9.9.1 The Persistence of Treatment Discontinuation
    • 9.9.2 Reducing Preservative Exposure
    • 9.9.3 Fixed-Dose Combinations and Procedural Delivery
  • 9.10 New Formulations & Delivery Routes
    • 9.10.1 Intracameral Implants
    • 9.10.2 Intraocular Lens Combination Platforms
    • 9.10.3 Ocular Surface Platforms
    • 9.10.4 Punctal Plug Delivery
    • 9.10.5 Injectable Posterior-Segment Routes: Intravitreal and Suprachoroidal
    • 9.10.6 Topical Platform and Formulation Innovation
    • 9.10.7 Oral and Nanotechnology-Based Approaches
  • 9.11 Geographic Outlook: Which Countries Offer the Highest Growth Potential?
  • 9.12 Which Drug Class Leads the Market?
  • 9.13 Strategic Recommendations
  • 9.14 Which Originators Outperform the Base Case?

List of Figures

  • Figure 1: Development of Glaucoma
  • Figure 2: Open-Angle Glaucoma
  • Figure 3: Angle-Closure Glaucoma
  • Figure 4: US Patent Expiration Dates for Key Innovator Glaucoma Drugs
  • Figure 5: Distribution of Glaucoma Drugs R&D Pipeline Candidates by Mechanistic Class (%)
  • Figure 6: Distribution of Glaucoma Drugs R&D Pipeline Candidates by Classification (%)
  • Figure 7: Glaucoma Adrenergic Modulator Pipeline Candidates
  • Figure 8: Glaucoma Cell, Gene, and RNA Therapy Pipeline Candidates
  • Figure 9: Glaucoma KATP Channel Modulator Pipeline Candidates
  • Figure 10: Glaucoma Neuroprotective and Emerging Mechanism Pipeline Candidates
  • Figure 11: Glaucoma Nitric Oxide Donor Pipeline Candidates
  • Figure 12: Glaucoma Prostanoid Modulator Pipeline Candidates
  • Figure 13: Glaucoma ROCK Inhibitor Pipeline Candidates
  • Figure 14: Glaucoma Drugs Near-Term Pipeline: Phase III and Preregistration Candidates 2026
  • Figure 15: Glaucoma Drugs Future Roadmap: 2026 - 2036
  • Figure 16: Glaucoma Drugs Value Chain
  • Figure 17: Expedited Development Programs and Glaucoma Applicability
  • Figure 18: US Reimbursement Pathways for Glaucoma Therapies by Product Format
  • Figure 19: European HTA Frameworks and Reimbursement Considerations for Glaucoma Drugs
  • Figure 20: Regulatory Status and Designation Profiles of Selected Glaucoma Programs
  • Figure 21: Global Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 22: Global Glaucoma Drugs Revenue Table ($ Million) and YoY Growth: 2026 - 2036
  • Figure 23: Global Glaucoma Drugs Revenue by Drug Class ($ Billion): 2026 - 2036
  • Figure 24: Glaucoma Drugs Revenue by Drug Class ($ Million): 2026 - 2036
  • Figure 25: Global Prostaglandin Analogs Revenue ($ Billion): 2026 - 2036
  • Figure 26: Global Beta Blockers Revenue ($ Billion): 2026 - 2036
  • Figure 27: Global Alpha Agonists Revenue ($ Billion): 2026 - 2036
  • Figure 28: Global Carbonic Anhydrase Inhibitors Revenue ($ Billion): 2026 - 2036
  • Figure 29: Global ROCK Inhibitors Revenue ($ Billion): 2026 - 2036
  • Figure 30: Global Glaucoma Combinations & Other Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 31: Global Glaucoma Drugs Revenue by Indication ($ Billion): 2026 - 2036
  • Figure 32: Glaucoma Drugs Revenue by Indication ($ Million): 2026 - 2036
  • Figure 33: Primary Open-Angle Glaucoma (POAG) Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 34: High-Tension POAG Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 35: Normal-Tension Glaucoma (NTG) Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 36: Primary Angle-Closure Glaucoma (PACG) Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 37: Ocular Hypertension (OHT) Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 38: Secondary Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 39: Congenital Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 40: Global Glaucoma Drugs Revenue by Distribution Channel ($ Billion): 2026 - 2036
  • Figure 41: Glaucoma Drugs Revenue by Distribution Channel ($ Million): 2026 - 2036
  • Figure 42: Hospital / Specialty Pharmacies Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 43: Retail Pharmacy Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 44: Online Pharmacies / D2C Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 45: Global Glaucoma Drugs Revenue by Originator vs Generic ($ Billion): 2026 - 2036
  • Figure 46: Glaucoma Drugs Revenue by Originator vs Generic ($ Million): 2026 - 2036
  • Figure 47: Branded Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 48: Generic Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 49: Global Glaucoma Drugs Revenue by Region ($ Billion): 2026 - 2036
  • Figure 50: Glaucoma Drugs Revenue by Region ($ Million): 2026 - 2036
  • Figure 51: Asia Pacific Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 52: Europe Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 53: Middle East & Africa Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 54: Latin & Central America Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 55: North America Glaucoma Drugs Revenue ($ Billion): 2026 - 2036
  • Figure 56: Glaucoma Drugs Market Revenue by Country ($ Million): 2026-2036
  • Figure 57: Australia Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 58: Brazil Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 59: Canada Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 60: China Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 61: Egypt Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 62: France Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 63: Germany Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 64: Greece Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 65: India Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 66: Israel Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 67: Italy Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 68: Japan Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 69: Mexico Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 70: Netherlands Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 71: Poland Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 72: Portugal Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 73: Russia Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 74: Saudi Arabia Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 75: South Africa Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 76: South Korea Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 77: Spain Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 78: Switzerland Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 79: Taiwan Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 80: Turkey Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 81: UK Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 82: USA Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 83: RoW Glaucoma Drugs Revenue ($ Million): 2026 - 2036
  • Figure 84: Global Glaucoma Drugs Revenue, 2026 - 2036 ($ Million)
  • Figure 85: M&A and Corporate Transactions Reshaping the Glaucoma Competitive Landscape
  • Figure 86: Consolidated Competitive Positioning of Leading Glaucoma Originators
  • Figure 87: Patent Expiration Status for Key Glaucoma Drugs (US)
  • Figure 88: Medicare Part B Reimbursement for Intracameral Glaucoma Implants (US)
  • Figure 89: Glaucoma Drug Delivery Routes by Commercial Maturity, 2026
  • Figure 90: Global Glaucoma Drugs Market Share by Drug Class (%): 2026